GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (XTER:FYB) » Definitions » Gross-Profit-to-Asset %

Formycon AG (XTER:FYB) Gross-Profit-to-Asset % : 1.26% (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Formycon AG Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Formycon AG's annualized Gross Profit for the quarter that ended in Dec. 2023 was €11.34 Mil. Formycon AG's average Total Assets over the quarter that ended in Dec. 2023 was €901.65 Mil. Therefore, Formycon AG's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 1.26%.


Formycon AG Gross-Profit-to-Asset % Historical Data

The historical data trend for Formycon AG's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Formycon AG Gross-Profit-to-Asset % Chart

Formycon AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.54 12.28 14.15 2.62 2.67

Formycon AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.47 2.39 1.61 3.99 1.26

Competitive Comparison of Formycon AG's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Formycon AG's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Formycon AG's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Formycon AG's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Formycon AG's Gross-Profit-to-Asset % falls into.



Formycon AG Gross-Profit-to-Asset % Calculation

Formycon AG's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=23.305/( (853.697+890.362)/ 2 )
=23.305/872.0295
=2.67 %

Formycon AG's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=11.338/( (912.944+890.362)/ 2 )
=11.338/901.653
=1.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Formycon AG Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Formycon AG's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Formycon AG (XTER:FYB) Business Description

Traded in Other Exchanges
Address
Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is a pharmaceutical company. It is engaged in the development of pharmaceutical and biopharmaceutical products and the development of drug delivery systems. Its focus is on treatments in ophthalmology and immunology as well as other chronic diseases. The company's pipeline in the biosimilar drugs category includes FYB201, FYB202, FYB203, and FYB207 for the treatment of COVID 19. It is also engaged in the provision of diagnostic laboratory services and works for third parties and the carrying out of diagnostic laboratory services.
Executives
Dr. Stefan Glombitza Board of Directors
Dr. Carsten Brockmeyer Board of Directors
Dr. Nicolas Combé Board of Directors

Formycon AG (XTER:FYB) Headlines

No Headlines